


This is a randomized, open-label, blinded endpoint evaluation, Phase 3 study comparing the effect of abelacimab relative to apixaban on VTE recurrence in patients with cancer.

Randomization into treatment groups will be stratified by region, cancer location (GI/GU cancers vs other locations), and symptomatic vs incidental thromboembolic events.

The study is comprised of 3 periods: 1) screening (up to 3 days [72 hours]), 2) study drug treatment period through the end of treatment (EoT) visit, and 3) follow up period through the End of Study (EoS) visit.

Figure 3-1 Study design



* Patients should receive SoC treatment during the screening period (See [Appendix 3](#) for recommended treatment during the screening period, and [Table 3.1](#) for transition to study treatment).